ALECTINIB, BRIGATINIB, AND LORLATINIB AS FIRST-LINE THERAPIES FOR ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Mudumba, R. [1 ]
Nieva, J. J. [1 ]
Padula, W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE142
引用
收藏
页码：S81 / S81
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [22] Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    Advances in Therapy, 2020, 37 : 971 - 972
  • [24] Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2020, 37 (02) : 971 - 972
  • [25] Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-Line Alectinib or Brigatinib
    Preeshagul, I.
    Abrahami, D.
    Li, B.
    Thomaidou, D.
    Duncan, K.
    Krulewicz, S.
    Rupp, M.
    Bauman, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S678 - S679
  • [26] First-line treatment of advanced ALK-positive non-small-cell lung cancer
    Gandhi, Shipra
    Chen, Hongbin
    Zhao, Yujie
    Dy, Grace K.
    LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 71 - 82
  • [27] A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer
    Wang, Wan-Qing
    Xu, Tao
    Zhang, Jing-Jing
    Wang, Yong
    Wang, Yao
    Zhang, Wei
    Zhu, Jian-Guo
    JOURNAL OF THORACIC DISEASE, 2023, 15 (04) : 1935 - 1947
  • [28] Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
    Ravasio, R.
    Tiseo, M.
    Pradelli, L.
    Bellone, M.
    Gervasi, A.
    Coffani, M.
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2019,
  • [29] Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Shang, Yuqi
    Guo, Hao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (03) : 367 - 372
  • [30] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
12345